The present invention relates to an improved and industrially advantageous process for the preparation of imatinib of formula I, or its mesylate salt with controlled level of genotoxic impurity of formula II, a key intermediate for imatinib.

The present invention relates an improved and cost-effective, industrially advantageous process for the preparation of pure aripiprazole,  wherein concerned impurity i.e. corresponding quinoline impurity, namely 7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)quinolin-2(1H)-one is reduced to an amount of less than...

The present invention relates to a cost effective, environment friendly industrially viable process for the preparation of 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepine-2-one, an intermediate used in the preparation of ivabradine, without using acid chloride intermediate and condensing agent

ABSTRACT "AN INDUSTRIAL PROCESS FOR THE PREPARATION OF 5-BROMO-2-FLUOROBENZONITRILE" The present invention provides an industrially advantageous process for the preparation of pure 5-bromo-2-fluorobenzonitrile, a precursor of key intermediates used in the synthesis of certain xanthine oxidase inhibitor compoun...

ABSTRACT “AN IMPROVED PROCESS FOR THE PREPARATION OF CLARITHROMYCIN BY SELECTIVE METHYLATION""    The present invention relates to a commercially viable and industrial advantageous process for preparation of clarithromycin via selective methylation of a hydroxy group at 6 position of erythromycin A derivative ...

The present invention provides a process for the preparation of 1-phenyl-3-dimethylaminopropane derivatives of formula I, and its pharmaceutically acceptable salts thereof from intermediate of formula II, wherein R1 can be selected from -OR2, halo, -CH2OR2, -SR2, -SOR2, -SO2R2, SO3H, -NO2, -NR2R2", -CONR2R2", carb...

The present invention provides an industrially advantageous process for the preparation of pure allyl protected keto derivative of formula I,  an intermediate of ezetimibe. Formula-I by using a novel O-allyl amide derivative of formula II. Formula-II wherein R is methyl or ethyl ...

The present invention relates to a commercially viable and improved process for preparation of tapentadol of formula I and its pharmaceutically acceptable salts, via novel intermediates tertiary hydroxy protected sulfonyl compound of formula III. wherein Rj is selected from hydrogen, straight chain or branched a...

ABSTRACT “A PROCESS FOR PREPARING AN INDOLINE DERIVATIVE” The present invention provides an improved, cost-effective and commercially viable process for preparing an indoline derivative of formula I, a key intermediate used in the synthesis of silodosin, through novel intermediates. Formula I ...

The present invention relates to a process for preparing pure olmesartan medoxomil of formula I, particularly, the present invention provides a process for preparing pure olmesartan medoxomil by detritylation of trityl olmesartan medoxomil.

"AN IMPROVED PROCESS FOR PREPARING PURE MINODRONIC ACID AND INTERMEDIATES THEREOF" ABSTRACT: The present invention relates to an industrially advantageous, cost-effective, and reproducible process for preparation of pure minodronic acid, including salts, hydrates and polymorphs thereof, by using ecofriendly proc...

The present invention provides an improved process for the preparation of highly pure bexarotene of formula I. The present invention also provides impurities of bexarotene, method of isolation and identification of these impurities, and use of these impurities as reference marker as well as reference standard. ...

The present invention provides a process for preparing pure argatroban of formula I, having reduced level of impurities by optimizing the reaction conditions of different stages. The present invention also provides novel impurities of argatroban and methods of identifying as well quantifying impurities. ...

The present invention relates to a novel and industrially advantageous process for the preparation of 5-substsituted indole derivative, particularly it relates to process for the preparation of 5-bromo-3-[(R)-l-methyl-pyrrolidin-2-ylmethyl]-lH-indol of formula I, a key intermediate for the synthesis of eletriptan o...

The present invention provides an effective and industrially advantageous process for purification of 2-(2-(3-(S)-(3-(7-chloro-2-quinolinyl)- ethenyl)-phenyl)-3-(hydroxy-propyl)phenyl-2-propanol of formula I, Formula I which is a key intermediate for the synthesis of montelukast or pharmaceutically acceptable ...

The present invention relates to an industrially advantageous process for the preparation of α form of imatinib mesylate, an inhibitor of tyrosine kinases, having residual solvents with in specified limits as per ICH guidelines.

The present invention provides a process for preparing pure rosuvastatin of formula I, or  pharmaceutically  acceptable  salts  thereof  through  rosuvastatin   1-(1-naphthyl)ethylamine salt of formula II, wherein wavy line (~) represent (R), (S) stereochemistry or racemate thereof.

The present invention relates to an improved and industrially advantageous process for preparation of eletriptan of formula I, or pharmaceutically acceptable salts thereof from  bromo  indole intermediate of formula II, through isolation of N-acetylated bromo indole intermediate of formula III, to elude carrying ...

ABSTRACT “Process for the preparation of Silodosin through Novel Salt of Cyano Hydroxy Intermediate.” The present invention provides an improved and efficient process for the preparation of silodosin of formula I and pharmaceutically acceptable salts thereof Formula I through novel tartrate salt of...

The present invention provides an improved, efficient, safe and convenient process for preparation of lisdexamphetamine and its pharmaceutically acceptable salts by using novel mixed anhydride intermediate. The present invention also provides a process for preparation of diamino protected amide compound namely BOC p...

The present invention relates to a novel polymorphic form I of rifaximin and process for preparation thereof. The novel polymorphic form I is characterized by powder x-ray diffraction pattern at 20, 5.2, 7.2, 8.4 and 8.7 degrees ±0.2 and water content within the range of 2.0 to 4.5%. The invention further provides p...

ABSTRACT PROCESS FOR PURIFICATION OF 4,5-DIMETHOXY BENZOCYCLO- BUTANE DERIVATIVES The present invention relates to an efficient and industrially advantageous process for purification of 4,5-dimethoxy benzocyclobutane derivatives, which are important key intermediates in the preparation of ivabradine hydrochlo...

The present invention relates to an industrially advantageous and improved process for preparation of dabigatran etexilate of formula I and its pharmaceutically acceptable salts.

ABSTRACT OF THE INVENTION Process for the preparation of pure Form B of Tapentadol Hydrochloride The present invention relates to an improved and industrially advantageous process for the preparation of pure Form B of tapentadol hydrochloride in consistent manner by treating tapentadol base with a suitable so...

The present invention provides an industrially advantageous, economical and improved process for preparation of minodronic acid including salts and hydrates thereof. The present invention also provides a process for the preparation of key intermediates of minodronic acid in high yield and high purity. ...

ABSTRACT OF THE INVENTION “Process for the preparation of rosuvastatin via novel intermediates.” The present invention provides an industrially advantageous and cost-effective process for preparation of rosuvastatin of formula I or pharmaceutically acceptable salts thereof, Formula I via novel inte...

The present invention relates to a process for the preparation of phenyl carbamate derivative of formula I, a key intermediate for the synthesis of quetiapine, by condensing 2-amino diphenyl sulfide with phenyl chloroformate in the absence of an organic solvent.

The present invention relates to an industrially advantageous and efficient process for the preparation of raltegravir potassium Form 3 from raltegravir by using potassium base and alcoholic solvent.

The present invention relates to an efficient and industrially advantageous process for preparation of 3-(2-bromo-4,5-dimethoxybenzene)propionitrile of formula I, with high purity and high yield,wherein compound of formula I is an important precursor of 1-cyano-4,5- dimethoxybenzocyclobutane, a key intermediate i...

The present invention relates to an improved and industrially advantageous process for the preparation of pure tapentadol hydrochloride Form B in consistent manner.

The present invention provides an improved process for the preparation of sunitinib of formula I, and its pharmaceutically acceptable salts thereof. Further, present invention also provides process for the preparation of form I of sunitinib malate.

The present invention provides an industrially advantageous process for the preparation of rosuvastatin of formula I, or pharmaceutically acceptable salts thereof.

NA

The present invention relates to an industrially advantageous process for the preparation of 0-desmethyl-venlafaxine, a venlafaxine metabolite, and pharmaceutically acceptable salts thereof by demethylating venlalaxme or salts theroi" using an alkali or alkaline earth metal salts of mercapto acids and their derivati...

NA

The present invention relates to highly pure Ropinirole or salt thereof and a process for preparing highly pure Ropinirole of structural Formula I, by reducing nitro compound of formula II, With hydrogen gas in the presence of a catalysts in  water to produce amino compound and cyclizing the resulting amino compou...

The present invention provides a process for the preparation of montelukast sodium through novel montelukast amine salt of formula I, wherein  (R)2NH  is  selected from  l-(l-naphthyl)ethylamine,  S-methyl-L-cysteine, diallylamine or isomers thereof.

The present invention relates to process for the preparation aripiprazole polymorph having an average particle size less than 100 µm using a specific solvent system and reaction condition for inducing precipitation.

The present invention provides an industrially advantageous process for the preparation of highly pure prulifloxacin of formula I and its pharmaceutically acceptable salts. The present invention also provides a novel process for the purification of prulitloxacin acid addition salt.

The present invention relates to an improved process for synthesizing highly pure nateglinide form B. More particularly, the present invention relates to the process for synthesizing highly pure nateglinide form B directly from nateglinide alkyl ester derivative. The present invention also relates to process for con...

The object of the present invention encompasses amorphous rimonabant and processes thereof. Another object of the present invention encompasses processes for converting crystalline form of rimonabant to amorphous rimonabant.

The present invention relates to an industrially advantageous process for the preparation of ezetimibe of formula I in high yields by using novel benzyl ester intermediates.

The present invention relates to the preparation of highly pure donepezil of Formula I or salt thereof,by hydrogenating indanonylidenyl compound of using platinum catalysts.

The present invention relates to an industrial process for the preparation of highly pure 2-[4-(4-choloro-butyryl) phenyl]-2-methyl propanol, a key intermediate in the preparation of Fexofenadine, from methyl 2-[4-(4-choloro-butyryl) phenyl]-2-methyl propanoate in presence of anhydrous alcoholic- hydrogen chloride. ...

The present invention relates to a process for the preparation of highly pure atomoxetine of formula I and pharmaceutically acceptable salts thereof The present invention also aims at novel processes for the preparation and purification of intermediates involved in the process of the present invention. ...

The invention encompasses amorphous ivabradine hydrochloride and its method of preparation thereof. An improved process for the preparation of crystalline ivabradine hydrochloride is also provided..

The present invention relates to an industrially advantageous process for the preparation of tetrahydrofuran antifungals preferably posaconazole of formula I. The present invention further relates to improved processes for preparing key intermediates useful in the preparation of posaconazole.

The present invention relates to highly pure Ropinirole or salt thereof and a process for preparing highly pure Ropinirole of structural Formula I, Formula I by reducing nitro compound of formula II, Formula II and cyclizing the resulting amino compound in situ using palladium on carbon in the presence of aqueous...

The present invention relates to an industrially advantageous process of making hisphosphonic acid or its salt in particular risedronic acid, [l-hydroxy-2(3-pyridinyl)ethylidene] his phosphonic acid, having Formula-I or its salts in high purity and high yields

The present invention provides an improved process for the preparation of temozolomide of formula I, by employing the mild reaction condition.

The present invention relates to an industrial process for the preparation of highly pure 2-[4-(4-choloro-butyryl) phenyl]-2-methyl propionic acid of Formula 1, a key intermediate in the preparation of Fexofenadine, by purifying with cyclohexane.

The present invention relates to an improved process for the preparation of bibenzimidazole derivative, particularly 4-methyl-6-( 1 -methyl benzimidazole-2-yl)-2-n-propylbenzimidazole of fomiula I, a key intermediate in the preparation of telmisartan.

The present invention provides to an improved process for the preparation of O-desmethyl-venlafaxine of formula I, by demethylating venlafaxine or its pharmaceutically acceptable salts thereof by using alkali metal sulphide under mild reaction conditions.

The present invention relates to anhydrous 3-(acetylamino)-l-propanesulfonic acid calcium salt (acamprosate calcium) of formula I and process of its preparation thereof.

The present invention  relates to  an  industrially advantageous  method for the purification of anastrozole of Formula I. Formula I wherein isoanastrozole of Formula VI. Formula VI present in crude anastrozole as an impurity, is removed by using gel purification.

The present invention provides a cost effective and industrially advantageous process for the preparation of ranolazine of formula I, Formula I by reacting 2,6-dimethylaniline derivative with chloroacetyl chloride in the presence of base in water optionally with water miscible solvent and resulting amide intermedi...

This invention provides a process for the preparation of highly pure duloxetine hydrochloride of formula I, from duloxetine free base via its acid addition salts. The invention also aims at providing a process for the purification of duloxetine hydrochloride, wherein the level of unwanted R-enantiomer is red...

The present invention provides a process for the preparation of indole derivatives, specifically N-methyl-1H-indole-5-ethanesulfonamide of formula I, involving novel intermediate, which is used as key intermediate for the synthesis of naratriptan of formula II, and its pharmaceutically acceptable salts thereof hig...

The present invention relates to novel process for the preparation of amorphous form of Clopidogrel hydrogen sulfate of the formula I from clopidogrel base by using a mixture of ketonic and halogenated solvent.

The present invention relates to the preparation of amorphous atorvastatin calcium of formula I,(Formula Removed) from (3R, 5R) tert.-butyl (6-{2-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-(l-methylethyl)-pyrrol-l-yl]-ethyl }-2,2-dimethyl {l,3-}dioxan-4-yl) acetate of formula II.

NA

The present invention relates to an industrially advantageous process for the preparation of imatinib of formula I, and its pharmaceutically acceptable salt, specifically imatinib mesylate.

The present invention relates to an improved process for the preparation of erythromycin A 9-oxime, a key intermediate in the preparation of clarithromycin, roxithromycin and azithromycin, directly from erythromycin thiocyanic acid salt using organic base in alcoholic solvent without isolating erythromycin A . ...

The present invention relates to novel crystalline forms of cinacalcet hydrochloride, a well known calcimimetic agent, and processes for preparing the same.

The present invention relates to an industrially advantageous, eco-friendly process for the preparation of rimonabant of formula-I, (Figure Remove) Formula-I staring from 1 -(4-chlorophenyl)-propan-1 -one in high yields and high purity by using mild reaction conditions and avoiding use of toxic and expensive reag...

The present invention relates to an improved process for synthesizing highly pure nateglinide form H. More particularly, the present invention relates to the process for synthesizing highly pure nateglinide form H directly from nateglinide alkyl ester derivative.

The present invention relates to a process for the preparation and purification of N-methyl-2-(4-hydrazino-phenyl) ethane sulfonamide hydrochloride of formula I, a key intermediate in the preparation of naratriptan and its pharmaceutically acceptable salts, using a source of hydrochloric acid or a solvent to enhanc...

The present invention relates to a novel process for the preparation of indole derivatives. In particular, present invention relates to the process for preparing naratriptan of formula I, and its salts using novel intermediates.

The present invention relates to an efficient and cost-effective process for the preparation   of   6-methylenandrost-l,4-diene-3,17-dione   (exemestane) by dehydrogenation of 6-methylenandrost-4-ene-3,17-dione using an dehydrogenating agent in the presence of an acid catalyst and at least one co-oxidant in an org...

The present invention provides an improved, industrial advantageous process for the preparation of gefitinib of formula I, and its pharmaceutically acceptable salts thereof in high yield and purity.

The present invention relates to an improved process for the preparation of 6-0-methylerythromycin A derivatives, intermediates of clarithromycin, by selective methylation of erythromycin A derivative in a mixture of a acyclic or cyclic alkanes having C6-C10 carbon atoms, and a polar aprotic solvent using a methylat...

The present invention provides an industrially advantageous process for the preparation of highly pure prulifloxacin of formula I and its pharmaceutically acceptable salts.The present invention also provides a novel process for the purification of prulifloxacin acid addition salt.

The present invention provides a process for the purification of cinacaicet hydrochloride by employing washing with aqueous solution or aqueous solution of suitable acid or slurry wash in a solvent or solvent mixture. The present invention provides a process for the purification of cinacaicet by gel purification to...

The present invention relates to the preparation of amorphous atorvastatin hemicalcium of formula I, from    (4R-cis)-(6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(l- methylethyl)-pyrrol-l -yl]-ethyl]-2,2-dimethyl-[ 1,3]-dioxan-4-yl-acetic acid tertiary-butyl ester of formula II. ...

The present invention relates to an industrially advantageous process for the purification of ezetimibe of formula I Specifically, the present invention relates to a process for the synthesis of enantiomerically and chemically pure ezetimibe which is substantially free of impurities.

The present invention relates to an improved process for synthesizing highly pure nateglinide form H. More particularly, the present invention relates to the process for synthesizing highly pure nateglinide form H directly from nateglinide alkyl ester derivative.

The present invention relates to an improved process for the preparation of 6-0-methylerythromycin A derivatives, intermediates of clarithromycin, by selective methylation of erythromycin A derivative in a mixture of a acyclic or cyclic alkanes having C6-C10 carbon atoms, and a polar aprotic solvent using a methylat...

The present invention relates to a novel and industrially advantageous process for the preparation of highly pure anhydrous Fexofenadine hydrochloride directly from fexofenadine base without isolating hydrous Fexofenadine hydrochloride.

The present invention provides an eco-friendly and cost-effective process for the preparation of piperidine derivative of formula I, a key intermediate useful for the synthesis of fexofenadine and its pharmaceutically acceptable salts thereof.

The present invention relates to pure Venlafaxine or salt thereof and a process for preparing highly pure Venlafaxine of structural Formula I, from N,N-didesmethyl venlafaxine or salt thereof of formula II, in the presence of hexamethylenetetramine.

The present invention relates to highly pure Venlafaxine or salt thereof and a process for preparing highly pure Venlafaxine of structural Formula I or salt thereof, by double methylation of N,N-didesmethyl venlafaxine or salt thereof using formaldehyde and formic acid in the presence of organic base. ...

The present invention provides an improved process for the preparation of ranolazine of formula I and pharmaceutically acceptable salts thereof, by reacting 2,6-dimethylaniline derivative with chloroacetyl chloride in the presence of base in water and resulting amide intermediate is reacted with piperazine and the ...

The present invention relates to an industrially advantageous process for the preparation of tetrahydrofuran antifungals preferably posaconazole of formula I. The present invention further relates to improved processes for preparing compound of formula II, a key intermediate in the preparation of posaconazole. ...

The present invention relates to an industrially advantageous process for the preparation of thiazolidine derivatives, such as pioglitazone of formula 1 and its pharmaceutically acceptable salts. This invention also provides novel synthetic intermediates useful in the process for the preparation of pioglitazone. ...

The present invention relates to an industrially advantageous and high throughput process for the preparation of imidazole-4,5-dicarboxylate derivative, particularly dialkyl-2-propylimidazole-4,5-dicarboxylate of formula I, wherein R represents a straight-chained or branched C1-C4 alkyl group a key intermediate in...

The present invention relates to an improved and industrially advantageous process for preparation of moxifloxacin hydrochloride of formula I.

The present invention provides novel acid addition salts of ivabradine of formula I, including their hydrates, solvates, anhydrous form, and non solvated form, both in amorphous and crystalline forms.

The present invention relates to an industrially advantageous process for the preparation of 2-phenyl-3-aroylbenzothiophenes, specifically raloxifene of formula I or a pharmaceutically acceptable salt thereof.

The present invention provides an improved and industrially advantageous process for the preparation of temozolomide of formula I. by  filtration  or centrifugation;  thus avoiding extraction  of temozolomide  from reaction mixture using large volumes of solvent.

The present invention provides an industrially advantageous and efficient process for the preparation of colesevelam hydrochloride using dried colesevelam and a source of chloride ion.

The present invention provides an efficient and industrially advantageous process for the preparation of ezetimibe of formula I, using novel intermediates.

The present invention provides a novel process for preparing cinacalcet of formula I, and pharmaceutically acceptable salts thereof. The present invention also provides novel nitrogen protected synthetic intermediates useful in the process of the present invention.

The present invention encompasses a process for the preparation of highly pure amorphous ivabradine hydrochloride by hydrolyzing acid addition salt of ivabradine with a suitable base, and treating ivabradine with alcoholic hydrogen chloride to get highly pure amorphous ivabradine hydrochloride. ...

The  present  invention  provides  a  process  for  the  preparing  l-phenyl-3-dimethylaminopropane derivatives of formula I, and its pharmaceutically acceptable salts thereof via novel intermediates.

The present invention provides a process for the preparation of androstenone derivatives; specifically 3-oxo-4-aza-5 alpha-androstene-17ß-carboxylic acid of formula I, a key intermediate for dutasteride.

The present invention relates to an isolated impurity of rimonabant, referred to as "Bis impurity" and removal thereof.

A process for the preparation of (S)-pregabalin of formula I containing cyanide ion content less than 5 ppm or free from the cyanide ion, by extracting its cyano diester intermediate of formula III, wherein R1 and R2 are the same or different and are hydrogen, C1-C6 alky I, aryl, benzyl, substituted benzyl, or C...

The present invention provides a process for the preparation of amorphous fexofenadine hydrochloride from fexofenadine via its weak acid addition salt. The present invention further provides a process for the preparation of amorphous fexofenadine hydrochloride from fexofenadine acid addition salt. ...

The present invention relates to an improved process for the preparation of pure 2-nitro-6-(2-di-n-propylaminoethyl)-phenylacetic acid of formula I or its salts in high yields, an intermediate in the preparation of an indolone derivative namely Ropinirple of Formula II,

“Process for the preparation of highly pure fesoterodine fumarate” The present invention relates to an improved and industrially advantageous process for the preparation of highly pure fesoterodine fumarate having assay in range 98 to 102% w/w and acceptable fumaric acid content, using a suitable crystallization ...

The present invention relates to an improved and industrially advantageous process for preparing pure tapentadol hydrochloride Form B in consistent manner.

The present invention relates to a novel process for the preparation of Form I of Clopidogrel hydrogen sulfate, namely methyl (+)-(S)-α-(o-chlorophenyl)-6,7-dihydrothieno [3,2-c] pyridine-5(4H)-acetate hydrogen sulfate of formula I.

INTERMEDIATES USEFUL FOR THE PREPARATION OF ANTIHISTAMINIC PIPERIDINE DERIVATIVE

The present invention relates to an industrially advantageous process for the preparation of highly pure a-ethyl-4-hydroxydesoxybenzoin of Formula-I, a key intermediate in the preparation of tamoxifen, useful in the treatment of breast cancer.

The present invention relates to a novel process for preparing amine derivatives of formula I, as calcimimetics, wherein Ar/ or Ar2 is either naphthyl or phenyl optionally substituted with 0 to 5 substituents each independently selected from the group consisting of lower alkyl, halogen, lower alkoxy, lower thioalky...

The present invention relates to novel crystalline form-Ill of 5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-A piperidin-l-yl)pyrazole-3-carboxamide namely rimonabant of formula-I,processes for its preparation and conversion to form-I of rimonabant.

"AN IMPROVED PROCESS FOR PREPARATION OF PURE POLYMORPHIC FORM GAMMA OF SILODOSIN" The present invention provides an improved and industrially advantageous process for preparation of pure polymorphic form gamma (?) of silodosin. More particularly, present invention relates to pure polymorphic form gamma (?) of sil...

The present invention provides an improved  efficient  safe and convenient process for preparation of highly pure deferasirox. The present invention also provides a novel process for purification of deferasirox by using quaternary ammonium hydroxides as a base.

ABSTRACT "AN INDUSTRIAL PROCESS FOR PREPARATION OF PHENYL PROPANOL DERIVATIVE" The present invention relates to an industrially advantageneous, cost effective, operationally safe method for the preparation of a phenyl propanol derivative of formula I, Formula I an important intermediate in prepara...

The present invention provides a process for the preparation of 1-phenyl-3-dimethylaminopropane derivatives of formula I, and its pharmaceutically acceptable salts thereof from cyano intermediate of formula wherein R1 can be selected from -OR2, halo, -CH2OR2, -SR2, -SOR2, -SO2R2, -SO3H, -NO2, -NR2R2", -CONR2R2", c...

The present invention relates to an improved and industrially advantageous process for the preparation of pure nateglinide form H in consistence manner directly from nateglinide alkyl ester. In particular, the present invention provides an improved and industrially advantageous process for the preparation of pure na...

The present invention relates to a novel process for the preparation of fesoterodine of formula I and pharmaceutically acceptable salts thereof,     Formula I via novel hydroxy carbonitrile intermediate of formula II;     Formula II a novel process for the preparation of novel hydroxy carbonitr...

The present invention relates to an efficient and industrially advantageous process for the preparation of pure 1H-pyrazolo[3,4-d] pyrimidine derivative. In particular the present invention provides a process for the preparation of pure 4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d] pyrimidine, a key intermediate of...

A process for the purification of cinacalcet hydrochloride of formula I,  Formula I to reduce the level of genotoxic impurities in cinacalcet hydrochloride by using a suitable solvent system.

The present invention provides a novel and an industrially advantageous process for the preparation of pure metaraminol or salts thereof. In particular, the present invention provides an industrially advantageous process for the preparation of enantiomerically pure metaraminol bitartrate of formula I Formula I N...

The present invention provides a novel and an industrially advantageous process for the preparation of pure metaraminol or salts thereof. In particular, the present invention provides an industrially advantageous process for the preparation of enantiomerically pure metaraminol bitartrate of formula I ...

The present invention provides an efficient and industrially advantageous process for purification of N-methyl-2-chloropyrimidine derivative, namely N-(2-chloropyrimidin-4-yl)-N,2,3-trimethyl-2H-indazol-6-amine of formula I, Formula I which is a key intermediate of pazopanib hydrochloride. The present invention a...

The present invention relates to an efficient and industrially advantageous process for purification of 4,5-dimethoxy benzocyclobutane derivatives, which are important key intermediates in the preparation of ivabradine hydrochloride.

The present invention relates to an efficient and industrially advantageous process for preparation of 5,6-dimethoxy-1-indanone of formula I, which is a key intermediate of donepezil hydrochloride, with improved yield, starting from 3-chloro-3',4'-dimethoxypropiophenone.

The present invention provides an improved process for the preparation of highly pure 2-(4-[l -hydroxy-4-[4-(hydroxy-diphenyl-methyl)piperidin-1 -yl]-butyl} -phenyl)-2-methyl-propionic acid (fexofenadine) of Formula I, or its salts thereof

The present invention relates to an improved, efficient, and industrially advantageous process for preparation of dipeptidyl peptidase-4 (DPP-4) inhibitor, saxaghptin monohydrate of formula I. A1- on .][sO Formula (T) Particularly, the present invention provides an improved process for the preparation of saxaghp...

The present invention relates to an improved, efficient, and industrially advantageous process for the preparation of Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib of formula I and its key intermediates. Particularly, the present invention provides a novel intermediates and process for the purification. M...

The present invention relates to an improved, efficient, and industrially advantageous process for preparation of solid forms of Bruton's Tyrosine Kinase (BTK) inhibitor, Ibrutinib of formula I. Particularly, the present invention provides process for the preparation of Crystalline Form A and Crystalline Form C ...

The present invention relates to process for the preparation of Atorvastatin of formula I, and intermediates thereof. Particularly, the present invention relates to an improved, efficient, and industrially advantageous process for the preparation of key intermediate, 2-[2-(4-Fluorophenyl)-2-oxo-1-phenylethyl]-4-...

The present invention relates to crystalline ivabradine hydrochloride of formula I and process for the preparation thereof. Particularly, the present invention relates to process for the preparation of crystalline ivabradine hydrochloride.

ABSTRACT An improved process for preparing highly pure donepezil hydrochloride The present invention relates to a process for preparing highly pure donepezil hydrochloride from 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-ylidenyl]methyl piperidine or acid addition salts thereof. Further the present invention rela...

ABSTRACT Crystalline salts of lisdexamfetamine The present invention relates to salts of pure amphetamine prodrug, in particular, L-lysine-d-amphetamine (known as lisdexamfetamine) and industrial advantageous process for preparation thereof. Further the present invention relates to the crystalline salts of lisd...

The present invention relates to an improved cost-effective process for preparing 5 eltrombopag olamine and its key intermediates. Further, the present invention provides an improved process for the preparation of compound of Formula IVa, an important starting intermediate of eltrombopag or eltrombopag olamine. ...

The present invention relates to an eco-friendly and efficient process for preparing mirabegron and its key intermediate. In a particular aspect of present invention relates to an improved process for the preparation of compound of formula 2 i.e. (2R)-2-hydroxy-N-[2-nitrophenyl) ethyl]-2-phenylacetamide or its salt...

The present invention is to provide an efficient process for preparing bempedoic acid of Formula 1 wherein by-product such as 4-methylbenzene sulfinic acid of Formula 6 is not carried forward to effluent and upcycling the compound of Formula 6 for preparing TosMIC. Further, the present invention provide an efficie...

The present invention provides an eco-friendly and efficient process for preparing bempedoic acid; wherein the process uses enzymatic transformations and/or a combination of chemical reactions at hydrolysis and reduction steps. The enzymatic or chemo-enzymatic reactions used in the process of the present inventi...

The present invention provides an economical process for preparing pure pentazocine and/or pharmaceutically acceptable salts thereof. Further, the present invention provides an improved process for the preparation of crystalline acid addition salt of pentazocine and its conversion to pure pentazocine of Form...